Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
In the province of Quebec, Canada, a 2 + 1 dose pneumococcal conjugate vaccine (PCV) program for children was implemented in 2004. PCV7 was replaced by PCV10 in 2009, by PCV13 in 2011 and by PCV10 in 2018, without catch-up in all instances. The objective was to estimate PCV13 effectiveness to prevent serotype 3 invasive pneumococcal disease in children aged less than 5 years, using 2010-2018 mandatory notification and laboratory surveillance data, an indirect cohort design and multivariate logistic regression models. A total of 29 cases of serotype 3 and 290 non-vaccine serotype cases as controls were analysed. Overall vaccine effectiveness (≥1 dose) was estimated at 59% [-39% to 88%]. During the first year after the last dose effectivness was 88% [47% to 97%] whereas no protection was observed thereafter. There was no trend towards increased effectiveness with the number of doses. PCV13 protection against serotype 3 IPD seems to be short-lived.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2023.07.049 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immunogenicity, safety and adverse events of sequential vaccination with a 10-valent pneumococcal conjugate vaccine (PCV10) and PPSV23 compared with PPSV23 alone in systemic lupus erythematosus.
Lupus Sci Med
September 2025
Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
Background: SLE has increased risk of invasive pneumococcal disease due to immune dysregulation and immunosuppression. European Alliance of Associations for Rheumatology recommendations suggest sequential vaccination with conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23). However, data on immunogenicity of sequential vaccination in SLE are limited.
View Article and Find Full Text PDFCorrigendum to "A phase 3 randomized trial (STRIDE-9) to evaluate the safety, tolerability, and immunogenicity of V116, a population-specific pneumococcal conjugate vaccine, in pneumococcal vaccine-naïve Japanese adults ≥65 years of age" [Vaccine 62 (2025) 127456].
Vaccine
September 2025
Merck & Co., Inc., Rahway, NJ, USA. Electronic address:
Adult Patients with Celiac Disease Are Under-Vaccinated Against Pneumococcal Disease: A Quality Improvement Study.
Dig Dis Sci
September 2025
Celiac Disease Program, Gastroenterology, Hepatology, and Nutrition, Digestive Disease Institute, Cleveland Clinic, Cleveland, OH, USA.
Purpose: Patients with celiac disease (CeD) are at increased risk of pneumococcal infections, and guidelines recommend vaccination against pneumococcal disease as a safe and effective strategy at reducing the risk of infection. The rate of vaccination amongst patients with CeD is unknown. The aim of this study was to evaluate current underlying vaccination rates and to improve vaccination rates through a quality improvement initiative.
View Article and Find Full Text PDFEvolving genomic landscape of pediatric pneumococcus in two Canadian urban centers following conjugate vaccination.
Front Microbiol
August 2025
Public Health Ontario, Toronto, ON, Canada.
Background And Aim: Pneumococcal conjugate vaccines (PCVs) have significantly reduced pediatric invasive pneumococcal disease (IPD). However, vaccine escape variants, the emergence of non-vaccine serotypes (NVTs), and antimicrobial resistance (AMR) remain ongoing concerns. We aimed to characterize long-term trends in serotype distribution, lineage composition, and AMR patterns among pediatric IPD cases following PCV introduction in two major Canadian urban centers: Calgary, Alberta, and Toronto, Ontario.
View Article and Find Full Text PDFRecommendations for pneumococcal vaccination of at-risk children: a global overview (2022-2024).
Vaccine
September 2025
Pfizer Vaccines and Antivirals, Medical and Scientific Affairs, Emerging Markets Region, France.
Background: Pneumococcal diseases have a major impact on childhood morbidity and mortality across the world. While any child could be infected, those with certain health conditions have an increased risk of infection and subsequent disease severity. This report provides an overview of pneumococcal vaccination policies focused on children considered to be at particular risk of pneumococcal disease.
View Article and Find Full Text PDF